A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

New England Journal of Medicine

Volumn 329, Issue 14, 1993, Pages 987-994

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LACTATE DEHYDROGENASE;

ADULT; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; TUMOR VOLUME;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMAN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGE; PROGNOSIS; REGRESSION ANALYSIS; RISK; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0027444652     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199309303291402     Document Type: Article

References (40)

1. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861
2. Rosenberg SA Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977; 61: 1023-1027
3. Fisher RI, Hubbard SM, DeVita VT, Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981; 58: 45-51
4. Shipp MA, Harrington DP, Klatt MM, Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757-765
5. Jagannath S, Velasquez WS, Tucker SL, Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986; 4: 859-865
6. Danieu L, Wong G, Koziner B, Clarkson B Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res 1986; 46: 5372-5379
7. Cowan RA, Jones M, Harris M, Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer 1989; 59: 276-282
8. Coiffier B, Lepage E Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989; 74: 558-564
9. Coiffier B, Gisselbrecht C, Vose JM, Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211-219
10. Velasquez WS, Jagannath S, Tucker SL, Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989; 74: 551-557
11. Hoskins PJ, Ng V, Spinelli JJ, Klimo P, Connors JM Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991; 9: 220-226
12. Dixon DO, Neilan B, Jones SE, Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295-305
13. Shipp MA, Yeap BY, Harrington DP, The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990; 8: 84-93
14. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2135
15. Lennert K, Mohri N, Stein H, Kaiserling E The histopathology of malignant lymphoma. Br J Haematol 1975; 31: Suppl: 193-203
16. Rappaport H. Tumors of the hematopoietic system. Sec. 3, Fasc. 8 of Atlas of tumor pathology. Washington, D.C.: Armed Forces Institute of Pathology, 1966.
17. Cox DR, Snell EJ. Analysis of binary data. 2nd ed. London: Chapman & Hall, 1989.
18. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
19. Mantel N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170
20. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220
21. Gray RJ Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics 1990; 46: 93-102
22. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont, Calif.: Wadsworth, 1984.
23. Therneau TM, Grambsch PM, Fleming TR Martingale-based residuals for survival models. Biometrika 1990; 77: 147-160
24. U.S. decennial life tables for 1979-81. Vol. 1. No. 1. United States life tables. Hyattsville, Md.: Department of Health and Human Services, 1985. (DHHS publication no. (PHS) 85-1150-1.)
25. Gordon LI, Harrington D, Andersen J, Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342-1349
26. Fisher RI, Gaynor ER, Dahlberg S, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006
27. Montserrat E, Garcia-Conde J, Vinolas N, ProMACE-CytaBOM vs. CHOP in the treatment of unfavorable lymphomas: a randomized trial. Blood 1991; 78: Suppl 1: 127a-127a abstract.
28. Gulati SC, Shank B, Black P, Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6: 1303-1313
29. McMaster ML, Greer JP, Wolff SN, Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma. Cancer 1991; 68: 233-241
30. Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2: Suppl 2: 123-129
31. Swan F Jr, Velasquez WS, Tucker S, A new serologic staging system for large-cell lymphomas based on initial beta2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989; 7: 1518-1527
32. Grogan TM, Lippman SM, Spier CM, Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988; 71: 1157-1160
33. Cowan RA, Harris M, Jones M, Crowther D DNA content in high and intermediate grade non-Hodgkin's lymphoma -- prognostic significance and clinicopathological correlations. Br J Cancer 1989; 60: 904-910
34. Cabanillas F, Pathak S, Grant G, Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med 1989; 87: 167-172
35. Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, Bloomfield CD Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. Ann Intern Med 1988; 108: 14-20
36. Schouten HC, Sanger WG, Weisenburger DD, Anderson J, Armitage JO Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. Blood 1990; 75: 1841-1847
37. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320: 1047-1054
38. Jalkanen S, Joensuu H, Klemi P Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma. Blood 1990; 75: 1549-1556
39. Sy MS, Guo Y-J, Stamenkovic I Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991; 174: 859-866
40. Zutter M, Hockenbery D, Silverman GA, Korsmeyer SJ Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood 1991; 78: 1062-1068